A PEGylated glucagon-like peptide-1 (GLP-1) agonist and glucagon antagonist hybrid peptide was engineered as a potential treatment for type 2 diabetes. To support preclinical development of this PEGylated dual-acting peptide for diabetes (DAPD), we developed a reproducible method for PEGylation, purifi cation, and analysis. Optimal conditions for site-specifi c PEGylation with 22 and 43 kDa maleimide -polyethylene glycol (maleimide-PEG) polymers were identifi ed by evaluating pH, reaction time, and reactant molar ratio parameters. A 3-step purifi cation process was developed and successfully implemented to purify PEGylated DAPD and remove excess uncoupled PEG and free peptide. Five lots of 43 kDa PEGylated DAPD with starting peptide amounts of 100 mg were produced with overall yields of 53% to 71%. Analytical characterization by N-terminal sequencing, amino acid analysis, matrix-assisted laser desorption/ionization mass spectrometry, and GLP-1 receptor activation assay confi rmed site-specifi c attachment of PEG at the engineered cysteine residue, expected molecular weight, correct amino acid sequence and composition, and consistent functional activity. Purity and safety analysis by sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS-PAGE), analytical ion-exchange chromatography, reversed-phase high-performance liquid chromatography, and limulus amebocyte lysate test showed that the fi nal products contained <1% free peptide, <5% uncoupled PEG, and <0.2 endotoxin units per milligram of peptide. These results demonstrate that the PEGylation and purifi cation process we developed was consistent and effective in producing PEGylated DAPD preclinical materials at the 100 mg (peptide weight basis) or 1.2 g (drug substance weight basis) scale.
INTRODUCTION
Glucagon-like peptide-1 (GLP-1) and glucagon share a common precursor, preproglucagon, which upon tissue-specifi c processing leads to production of GLP-1 in the intestine and glucagon in the pancreas. 1 GLP-1 and glucagon and their G-protein-coupled receptors show a high degree of homology, but each is highly selective for its respective binding partner. [2] [3] [4] GLP-1 and glucagon have opposing effects on blood glucose, making them highly attractive therapeutic targets for the treatment of type 2 diabetes. GLP-1 induces glucose-dependent insulin secretion in the pancreas without provoking hypoglycemia, while glucagon stimulates glycogenolysis and gluconeogenesis in the liver, resulting in elevation of plasma glucose. 5 , 6 Therapies based on the individual activities of either GLP-1 or glucagon are being pursued, including a GLP-1 receptor agonist and a glucagon receptor antagonist. A dual-acting peptide for diabetes (DAPD) was engineered to activate the GLP-1 receptor yet inhibit the glucagon receptor. 7 To prolong the duration of action, DAPD was conjugated with a single polyethylene glycol (PEG) at the introduced C-terminal cysteine.
A major hurdle for clinical development of PEGylated proteins and peptides is the establishment of a consistent manufacturing-scale process with reproducible analytical techniques to characterize the fi nal product. 8 The ability of free cysteine-containing peptides to readily form disulfi des can further complicate the production process. In this article, we describe an effective and reproducible method for production of PEG-DAPD at the 100 mg scale by peptide weight or the 1.2 g scale by drug substance weight to support its development as a potential therapeutic for type 2 diabetes. A series of analytical and functional assays were developed to support PEGylation and purifi cation development and to characterize PEGylated DAPD used in preclinical studies.
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16/60 Superdex 30 prep grade (pg), and HiPrep Sephadex G-25, supplied by GE Healthcare (Piscataway, NJ); and Toyopearl matrixes (Ether 650M and Phenyl 650M), supplied by TOSOH Bioscience (Montgomeryville, PA). All other chemicals used were multicompendial grade manufactured under current good manufacturing practices (cGMPs), supplied by Mallinckrodt Baker (Philipsburg, NJ). Pyrotell and Control Standard Endotoxin were supplied by Associates of Cape Cod (Falmouth, MA). Limulus amebocyte lysate (LAL) reagent water was supplied by BioWhittaker (Walkersville, MD).
Optimization of the PEGylation Reaction
DAPD at 0.5 mM concentration (peptide dry weight) was incubated with varying amounts of 22 kDa mPEG-MAL or 43 kDa mPEG2-MAL in a buffer containing 0.1 M phosphate, 0.15 M NaCl, and 0.1 M EDTA over a pH range from 5.8 to 8.0 and at ambient temperature for 0 to 4 hours. PEGylation reactions were quenched with 2 molar excess of dithiothreitol (DTT) relative to the PEG concentration. The extent of the PEGylation reaction is inversely proportional to the amount of free peptide and was a key factor for choosing the appropriate PEGylation conditions. PEGylation effi ciency was monitored by sodium dodecyl sulfate -polyacrylamide gel electrophoresis (SDS-PAGE) using NuPAGE 4% to 12% Bis-Tris gels from Invitrogen (Carlsbad, CA), performed under reducing conditions in 2-morpholinoethanesulfonic acid (MES) buffer and followed by staining with GelCode from Pierce (Rockford, IL) or a barium-iodine solution. 9 DAPD and PEGylated DAPD concentrations were determined either using amino acid analysis or by measuring the UV absorbance at 280 nm using a DAPD extinction coeffi cient of 2.19 mL/mg/cm (peptide mass = 3760 kDa).
Cation Exchange Chromatography
A PEGylated peptide-containing reaction mixture was applied to either a 4.5 mL (1.1 × 4.7 cm) SP Sepharose column or a 2.2 mL (1.1 × 2.3 cm) CM Sepharose column previously equilibrated with 10 mM phosphate, pH 6.5. The loading was 1.17 A 280 peptide per milliliter of gel (or 1.17 AU/mL) and 1.6 A 280 peptide per milliliter of gel (or 1.6 AU/mL) for the SP Sepharose and CM Sepharose column, respectively. All peptides were found to bind, and they were eluted in a ~200 to 350 mM concentration of NaCl when a salt gradient from 0 to 500 mM was applied (at pH 6.5) over 20 column volumes (CV). The PEGylation reaction mixture was also applied to 1 mL (1.1 × 1.1 cm) of either the FractoPrep SO, 3 the SP Sepharose, or the CM Sepharose column at pH 4.5 (25 mM Tris, 63 mM acetic acid) until the breakthrough peak started to emerge. Bound peptides were eluted in a pH gradient to 9.5 (50 mM Tris, 3 mM acetic acid), and recovery yields were determined by A 280 measurement.
Hydrophobic Interaction Chromatography
The solubility of PEGylated DAPD solution is low in the presence of high salt. The highest concentration of ammonium sulfate allowed to completely dissolve PEG-modifi ed DAPD was determined to be 0.75 M. Ammonium sulfate was added to a PEGylated peptide-containing reaction mixture to 0.75 M and loaded, at 1.7 A 280 peptide per milliliter of gel, onto a 2 mL (1.1 × 2 cm) Toyopearl Phenyl column equilibrated with 0.75 M ammonium sulfate, pH 5.0, and the binding was only 1 A 280 peptide per milliliter of gel. For elution, the ammonium sulfate concentration was decreased in a linear gradient to 0 M, and bound peptides were eluted in 0.6 to 0.2 M ammonium sulfate. When the loading ammonium sulfate concentration was reduced to 0.5 M, the reaction mixture bound to neither Toyopearl Phenyl 650M nor Toyopearl Ether 650M.
Size-Based Separation
A pool of PEG-modifi ed DAPD from the SP and CM Sepharose columns was applied to 120 mL (1.6 × 60 cm) Superdex 30 pg, 53 mL (2.6 × 10 cm) HiPrep Sephadex G-25, or a stirred cell using a YM10 membrane. The load volume was either 17% or 8% CV for the Superdex 30 pg and 9% CV for the Sephadex G-25 column. The linear fl ow rate was 28 to 30 cm/hr.
Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) was performed on an Applied Biosystems Voyager RP instrument (Foster City, CA) in positive, linear mode. A calibration mixture, composed of bovine insulin (5733 Da), thioredoxin (11 673 Da), and apomyoglobin (16 951 Da) (Applied Biosystems), was used to calibrate the m/z range. Samples were mixed with the matrix, composed of saturated sinapinic acid (Sigma Aldrich, St Louis, MO) in 70% trifl uoroacetic acid (TFA)/30% acetonitrile, then applied to the MALDI target plate and allowed to crystallize. A laser intensity of 2000 V was applied to the target spots, and an accelerating voltage of 25 kV was applied to the ions. Spectra provided were an accumulation of 80 laser shots.
N-Terminal Sequencing
N-terminal sequencing was conducted on an Applied Biosystems (Foster City, CA) Procise 494 sequencer using the standard operation procedure recommended by the manufacturer. Relevant sequencing chemicals and reagents were obtained from Applied Biosystems. Using a calculated mass of 3750 for 43 kDa PEG-DAPD (based on peptide weight) and DAPD with a concentration of ~0.8 mg/mL, each sample was diluted 1:10 into 0.1% TFA (5 m L + 45 m L diluent). Exactly 9.3 m L (200 pmol) of sample was then transferred onto a Biobrene (Applied Biosystems, Foster City, CA) treated glass fi ber fi lter. The sample cartridge was then assembled and placed onto the instrument. The sequencer was programmed to collect 33 cycles of amino acids for each sample analyzed. The repetitive yield of the b -lactoglobulin control was 96.5%, meeting the instrument specifi cations of ≥ 94%. Data analysis was conducted using the Model 610A, version 2.1, software package provided by the manufacturer.
Amino Acid Analysis
Glass hydrolysis tubes were obtained from Waters Corporation (Milford, MA). Hydrochloric acid, 6N sequanal grade and the protein standard bovine serum albumin (BSA) at a concentration of 2.0 mg/mL were purchased from Pierce (Rockford, IL). Amino acid calibration standards, internal standards, and the derivatizing reagents o-phthalaldehyde (OPA) and 9-fl uorenylmethyl-chloroformate (Fmoc) were purchased from Agilent Technologies (Wilmington, DE). Hydrolysis of the polypeptide bonds was conducted using 6 N HCl at 110°C for 22 to 24 hours under vacuum. The free amino acids were reacted with OPA (in the presence of 3-mercaptopropionic acid) for primary amino acids and Fmoc for secondary amino acids. The derivatives were separated by reversed-phase HPLC (Agilent 1090 HPLC system) and quantifi ed by comparison to amino acid calibration standards. Internal standards were included in all analyses.
Analytical Ion-Exchange Chromatography
Analytical ion exchange was performed using the ÄKTAex-plorer (GE Healthcare Bio-Sciences Corp., Piscataway, NJ) system. The sample was applied to a Mono S HR 10/10 column (GE Healthcare), equilibrated with 10 mM phosphate, 20 mM NaCl, pH 6.5, at a linear velocity of 153 cm/hr (2 cc/min). Following loading, the column was washed with 5 CV of the equilibration buffer. After washing, the salt concentration was increased in a linear gradient (from 2% to 100%) to 1 M over 20 CV for elution. The amount of residual unreacted mPEG2-MAL in purifi ed PEGylated DAPD was estimated by comparing the mPEG2-MAL peak area (in the fl ow-through fraction) to peak areas determined for an mPEG2-MAL standard curve generated by the same method.
Reversed-Phase HPLC
Reversed-phase HPLC was used to estimate the amount of free DAPD in the PEG-DAPD sample. PEG-DAPD was run on a C18 HPLC (Beckman System Gold), using a 2 mL loop and fl ow rate of 1 mL/min with the following program: 5 minutes of Buffer A (0.1% TFA/H 2 0) followed by 30 minutes of gradient to 100% Buffer B (0.1% TFA/acetonitrile [ACN]).
LAL Test
LAL is an aqueous extract of blood cells (amebocytes) from the horseshoe crab, Limulus polyphemus . A series of 2-fold dilutions was made for PEGylated DAPD. The LAL test was performed by adding 0.1 mL Pyrotell, containing an aqueous extract of amebocyte of L polyphemus, to 0.1 mL of the test sample PEGylated DAPD in a 10 × 75 mm depyrogenated, fl int (soda lime) glass reaction tube. The reaction solution was mixed thoroughly and placed immediately in a noncirculating water bath at 37°C ± 1°C for 60 ± 2 minutes. At the end of the incubation, the tube was removed from the water bath and inverted. If a gel formed and remained intact in the bottom of the tube after inversion of 180°, the test was positive. The endotoxin concentration of the sample was determined by using a standard curve of control standard endotoxin ( Escherichia coli ).
Measurement of Peptide Signaling Through GLP-1 Receptor
Rat insulinoma (RINm5F) cells were maintained in RPMI 1640 medium containing 5% fetal bovine serum (JRH Biosciences, a division of Sigma-Aldrich Corp., St Louis, MO) and 1% antibiotic-antimycotic solution (Invitrogen) at 37°C in a humidifi ed 5% CO 2 incubator. Seeded in 96 well plates and grown overnight were 1.5 × 10 5 RINm5F cells per well. The cells were washed twice with phosphate-buffered saline (PBS). The cells were incubated with peptide in HEPES-PBS containing 1% BSA and 100 m M 3-isobutylmethylxanthine (IBMX) for 15 minutes at 37°C. The cells were lysed, and intracellular cAMP was determined using the cAMP Scintillation Proximity Assay direct screening assay system (GE Healthcare).
RESULTS AND DISCUSSION

Optimization of the PEGylation Reaction
In an earlier publication, we described the engineering of a long-acting dual GLP-1 agonist and glucagon antagonist peptide as a potential therapeutic for type 2 diabetes. 7 The C-terminus of this DAPD was determined to be the optimal position to introduce a cysteine residue to enable sitespecifi c attachment of long-chained PEG. To scale up production of PEGylated DAPD for clinical studies, we fi rst optimized PEGylation conditions with the 22 kDa mPEG-MAL. The pH optimization experiment performed at ambient temperature for 30 minutes indicated that the PEGylation reaction was highly effi cient for pHs ranging from 5.8 to 8, as confi rmed by the disappearance of the free peptide band at 4 kDa and the appearance of the PEGylated band at ~40 kDa ( Figure 1A ). The 7 kDa band corresponds to the oxidized dimer peptide because when the same samples were run on reducing gels, DAPD migrated as a single band at 4 kDa and the dimer band disappeared (data not shown). Mass spectrometry revealed that the dimer had a mass of 7514 Da (data not shown), confi rming the disulfi de band formation. To maintain the equilibrium between disulfi de formation and dissociation, the dimer converted to the monomer peptide as more of the PEG-peptide conjugate formed over time. The apparent molecular weight of PEG-DAPD on the gel is much greater than the theoretical molecular weight because of heavy hydration of the PEG moiety. To minimize potential side reactions with amines at higher pH, pH 6.0 was chosen for the next set of optimization studies.
To optimize reaction time, the PEGylation reaction was performed at pH 6.0 from 0.2 minutes to 4 hours. The result showed that the reaction went to completion in 5 minutes or less ( Figure 1B ) . A reaction time of 30 minutes was chosen for the next set of optimization studies to ensure a complete site-directed PEGylation reaction without the formation of any unwanted side reactions.
To determine the optimal PEG-to-peptide ratio for the PEGylation reaction, 22 kDa mPEG-MAL with a concentration ranging from 2-to 50-fold molar excess over the concentration of DAPD was reacted with DAPD at pH 6.0 for 30 minutes. The concentration of peptide was kept at 0.5 mM to minimize dimerization and maintain peptide solubility. The minimum molar PEG-to-peptide ratio to achieve maximum PEGylation was determined to be ~1:1 for both 22 kDa and 43 kDa PEG reactions ( Figures 1C and 1D ) . No reaction was detected with the Cys-deleted DAPD, confi rming the high specifi city of PEGylation at the C-terminal cysteine of DAPD. The optimized reaction parameters described above were further adjusted specifi cally for DAPD modifi cation with the 43 kDa mPEG2-MAL. DAPD was not always completely soluble when resuspended to 1.88 mg/mL (or 0.5 mM) in a reaction buffer consisting of 100 mM phosphate, 150 mM NaCl, and 100 mM EDTA, pH 6.0. When the phosphate buffer concentration was reduced from 100 mM to 10 mM, the solubility of the peptide improved. EDTA was initially added to prevent the reoxidation of disulfi des that might form intermolecularly through the cysteine located at the C-terminus of DAPD. Nonetheless, following the PEGylation of DAPD, only PEGylated peptide was observed -not PEGylated dimer species (see below). Thus, EDTA was unnecessary for the reaction. Salt was initially included to prevent possible nonspecifi c interactions, but these interactions did not interfere with PEGylation, as the removal of salt did not appear to affect PEGylation (data not shown). The lower salt level has the added advantage of allowing the PEGylation reaction to be directly applied to a cation exchange column without further dilution, thereby streamlining the process. DTT was replaced by L-cysteine to quench the reaction because of DTT ' s possible in vivo toxicity. The fi nal condition for PEGylation was 0.5 mM DAPD reacted with 1.5-fold molar excess of the 43 kDa mPEG2-MAL in 10 mM phosphate, pH 6.5, at room temperature for 0.5 hours. 3-7) or 43 kDa mPEG-MAL (lanes 9-13) at pH 6.0 and room temperature for 30 minutes. DAPD indicates dual-acting peptide for diabetes; mPEG, methoxy polyethylene glycol; MAL, maleimide.
Purifi cation Process Development
PEGylated DAPD generated according to the optimized PEGylation procedure was used as a starting material for purifi cation process development. Our initial purifi cation strategy attempted to use a single column; specifi cally, cation exchange chromatography was used to resolve uncoupled PEG, free peptide, and PEGylated peptide in a single-unit operation based on the fact that both free and PEG-modifi ed peptides carry positive charges at the operating pH, but not PEG. Additionally, cation exchange chromatography might also separate free peptide from PEGylated peptide because the PEG-modifi ed peptide theoretically would bind less tightly to the cation exchange resin than the free peptide, because of steric interference from the attached PEG. However, SDS-PAGE analysis showed that a small amount of free peptide coeluted with the PEGylated peptide in most of the fractions collected from both SP Sepharose and CM Sepharose runs (data not shown). Hydrophobic interaction chromatography (HIC) was also found ineffective in separating the 2 forms of DAPD, as SDS-PAGE analysis showed that all fractions, column bound or unbound, contained both the free and the PEG-modifi ed peptides (data not shown). Thus, an additional separation method was needed to remove the small amount of free peptide impurity.
Cation exchange chromatography was selected over HIC as the initial capture step for purifying PEGylated DAPD because of its low solubility in ammonium sulfate and lower capacity in HIC binding. To choose a cation exchange matrix, the binding capacity of 3 matrixes was compared. The binding for EM FractoPrep SO, 3 SP Sepharose, and CM Sepharose was 1.4, 1.5, and 1.3 AU per mL of gel which corresponds to 0.64, 0.71, and 0.58 mg per mL of gel on the peptide weight basis. SP Sepharose was chosen because of its slightly higher binding capacity and easy accessibility.
To completely eliminate the unreacted DAPD, which may interfere with the functional assay, as the free peptide is more potent than the 43 kDa PEGylated DAPD (see below), a second purifi cation step was needed to separate DAPD and PEG-DAPD based on the large size difference. HiLoad 16/60 Superdex 30 pg, HiPrep Sephadex G-25, and stirred cell equipped with a YM10 (10 000 molecular weight cutoff) membrane were compared in their ability to completely remove free peptide. The matrix of Superdex 30 pg is highly cross-linked porous agarose, covalently bound with dextran, and is suitable for either fractionation when a good resolution is desired or group separation that allows for a bigger sample application. HiPrep Sephadex G-25 is also ideal for group separation. The molecular weight for group separation with Superdex 30 pg and HiPrep Sephadex G-25 is <10 000 and <5000, respectively. The absorbance-based yield analysis indicated that greater than 90% of the PEG- modifi ed DAPD applied was recovered. SDS-PAGE analysis showed that additional removal of free peptide by either size exclusion columns or a membrane-based fi ltration device was achieved and that all methods showed comparable results (data not shown). Both the membrane-based fi ltration step and size exclusion chromatography were included in the fi nal purifi cation process scheme to ensure maximum removal of the free peptide.
Preparation of PEGylated DAPD for Preclinical Studies
To produce the 5 batches of PEGylated DAPD used in preclinical studies, 0.5 mM DAPD was reacted with 1.5-fold molar excess of the 43 kDa mPEG2-MAL in 10 mM phosphate, pH 6.5, at room temperature for 0.5 hours and quenched by 2 molar excess of cysteine over the mPEG2-MAL. A 3-step purifi cation process consisting of cation exchange chromatography on SP Sepharose, membrane fi ltration on stirred cell, and size exclusion chromatography on Superdex 30 pg was used to purify PEGylated DAPD ( Figure 2 ). Average ± SD yield from 5 separate preparations for the cation exchange step was 84% ± 5%; for the membrane fi ltration step, 84 ± 12%; and for the size exclusion step, 87% ± 9%. The overall yield was 63% ± 7%.
Analytical Characterization of 43 kDa PEG-DAPD
The 43 kDa PEG-DAPD preclinical batches were characterized by a series of analytical methods to confi rm product E232 safety, identity, strength, purity, and potency. SDS-PAGE followed by protein and PEG staining was used to confi rm that the purifi ed PEG-DAPD contained both PEG and the peptide ( Figure 3 ) . Peptide composition and concentration was confi rmed by amino acid analysis (data not shown). The amount of peptide impurity was found to be ~1% by reversed-phase HPLC based on the integration of the PEG-DAPD peak vs the putative DAPD peak on the left ( Figure  4A ). The purifi ed 43 kDa PEG-DAPD was also loaded onto SDS-PAGE at increasing amounts to determine peptide impurity levels ( Figure 4B ). The amount of free peptide impurity was estimated to be <1% based on the lowest detection limit at 0.03 nmol (Lane 5) for the unmodifi ed peptide and that no free peptide was detected at the highest level of 43 kDa PEG-DAPD loaded (2.7 nmol, Lane 7).
The fi rst 20 amino acids of DAPD were confi rmed by N-terminal sequencing. However, a signifi cant drop in amino acid yield in cycle 4 followed by a steady drop in recovery thereafter suggested signifi cant washout of sample, most likely because of the presence of the PEG, as the drop was not as signifi cant in the sequencing of the nonPEGylated peptide. This, together with the fact that no reaction was detected with the Cys-deleted DAPD, suggests that PEGylation is specifi c for the C-terminal cysteine of DAPD.
MALDI-MS confi rmed the predicted mass of 43 kDa PEG-DAPD. Uncoupled 43 kDa PEG yielded a broad spectral peak at ~40 to 50 kDa and centered at 43 to 44 kDa ( Figure  5A ). The broad spectrum is due to the heterogeneous population of the PEG polymer species. 10 , 11 The 43 kDa PEG-DAPD gave a broad spectral peak centered between 47 and 48 kDa, as expected ( Figure 5B ), confi rming that a single PEG was reacted with a single peptide. The peak observed at ~24 kDa represents the doubly charged ion. A small rise in the baseline was observed at 94 kDa because of the MALDI-induced dimer rather than a second PEG chain bound to the peptide. The presence of free PEG in a sample containing 43 kDa PEG-DAPD would not be detected by this method because of the heterogeneity of the polymeric samples and the lower effi ciency of ionization of free PEG. Although a relatively low laser power was applied, the MALDI process causes cleavage to a low percentage of the PEG-peptide bonds, leading to free peptide and PEG. Thus, this method cannot be used to accurately quantify the amount of free DAPD.
Analytical cation exchange chromatography was used for monitoring the amount of unreacted PEG ( Figure 6 ). A small amount of the unreacted PEG was found in the fl owthrough fraction, as detected by A 215 nm absorbance. PEG does not absorb at A 280 nm, so that this A 215 nm peak in fl ow-through could also be due to the smaller A 280 nm peak in fl ow-through as a result of a small portion of PEGylated peptide not binding to the column. A 215 nm standard curves generated with 43 kDa PEG (quenched with cysteine) reaction can be performed under simple and well-known conditions. The separation techniques are straightforward and familiar. PEGylation and purifi cation can readily be performed at the 100 g (peptide weight basis) or 1.2 kg (drug substance basis) scale, involving vessels and chromatography columns of less than 250 L. The projection represents the most conservative possible case. Improvements in process performance can be expected even if their magnitude cannot be predicted. These include increasing reactant concentrations, reducing the number of purifi cation steps, increasing the yield of each unit operation, reducing the reaction excess of mPEG2-MAL, and increasing the loading of chromatography columns.
CONCLUSION
Although protein PEGylation has been well established, few examples of successful PEGylation of peptides have been reported to date. This is most likely due to the higher allowed for an approximation of the amount of 43 kDa PEG impurity in the 43 kDa PEG-DAPD sample: <5%.
To facilitate in vitro and in vivo functional testing of 43 kDa PEG-DAPD, all lots were also tested for endotoxin levels. The LAL test showed that all lots had endotoxin levels less than the detection limit of 0.2 endotoxin units (EU)/mg.
GLP-1 receptor activity was assessed for DAPD, 22 kDa PEG-DAPD, and 43 kDa PEG-DAPD against the benchmark GLP-1 peptide ( Figure 7 ) . The different lots of 43 kDa PEG-DAPD showed reproducible GLP-1 receptor activation, although to a lesser extent than 22 kDa PEG-DAPD, DAPD, and GLP-1, as expected following modifi cation with a higher PEG molecular weight. 7
Process Scale-Up Feasibility
The high overall purifi cation yield, the low SD for the yield at each step of purifi cation, and the extensive analytical characterization detailed above demonstrate that PEGylated DAPD can be reproducibly synthesized and purifi ed. The PEGylation 
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likelihood of a reduction in activity upon PEGylation of many peptides. The small size difference between the PEGylated peptide and PEG, the heterogeneity of PEG, and the ability of PEG to shield the peptide charges have made it extremely challenging to purify PEGylated DAPD in a consistent manner and with a high degree of purity.
We have developed a highly effi cient and reproducible PEGylation procedure for site-specifi c PEGylation of a 32-mer dual-acting peptide for type 2 diabetes. A nearly complete reaction was achieved at ambient temperature with a wide range of pH from 5.8 to 8, within 5 minutes, and a slight molar excess of PEG over the peptide. A purifi cation process was developed to purify PEG-modifi ed DAPD that included cation exchange chromatography to remove the unreacted PEG, membrane fi ltration to separate the uncoupled peptide and to reduce the pool volume before loading onto the size exclusion column, and size exclusion chromatography to resolve the trace amounts of free peptide and to formulate the product in phosphate-buffered saline (pH 7.4). The average overall yield of four 43 kDa PEG-DAPD lots was 63%. Analyses of 43 kDa PEG-DAPD preparations showed consistent product safety, identity, strength, purity, and potency and that the preparations were monoPEGylated; possessed the expected sequence and amino acid composition; contained <1% of free peptide, <5% uncoupled PEG, and <0.2 EU/mg endotoxin; and had consistent GLP-1 receptor activation. The PEGylation and purifi cation development studies described here demonstrate that 43 kDa PEG-DAPD can be synthesized and purifi ed reproducibly and reliably at the 100 mg scale based on peptide weight. Moreover, the series of analytical methods developed to fully characterize the PEGylated product establishes a blueprint for future qualifi cation of PEGylated peptides.
As far as we are aware, PEGylated DAPD is the only PEGylated peptide that can be produced on a scale suffi cient to support extensive preclinical studies. PEGylated DAPD has dramatically prolonged pharmacological activity in vivo when compared with nonmodifi ed GLP-1, which has a halflife of less than 5 minutes in vivo. PEGylated DAPD has demonstrated glucose-lowering activity in a glucose tolerance test for up to 65 hours following subcutaneous injection in rats. 12 This prolonged activity confi rms the improved stability and reduced clearance of the PEGylated peptide.
